Table 2.
Overview of the functions of cysteine cathepsins in glial cells
| Glial cell type | Cysteine cathepsin | Function | References |
|---|---|---|---|
| Microglia | Cathepsin B | Indirectly induces microglia-dependent Aβ accumulation in neurons via β-secretase activity | (Wu et al. 2017) |
| Promotes Aβ phagocytic clearance in Alzheimer’s disease | (Cappellano et al. 2013; Comi and Tondo 2017; Nakanishi 2020b; Jiang et al. 2025) | ||
| Activates the NLRP3 inflammasome and triggers IL-1β release via caspase-1 | (Halle et al. 2008; Terada et al. 2010; Hanamsagar et al. 2011; An et al. 2016; Xu et al. 2018a; Bai et al. 2018; Chevriaux et al. 2020) | ||
| Promotes neurotoxic polarization and neuroinflammation via NF-κB activation | (Wendt et al. 2009; Ni et al. 2015, 2019; Inoue et al. 2022) | ||
| Impairs memory by degrading mitochondrial transcription factor A and producing reactive oxygen species and pro-inflammatory mediators | (Ni et al. 2019) | ||
| Induces neuronal apoptosis via caspase-3 activation | (Kingham and Pocock 2001) | ||
| Triggers apoptosis through Bid activation | (Zhang et al. 2023c) | ||
| Cathepsin C | Promotes neurotoxic polarization and neuroinflammation via protein kinase C/p38MAPK/NF-κB activation | (Liu et al. 2019; Zhao et al. 2021) | |
| Enhances neuroinflammation by inducing C-C motif chemokine ligand 2 and C-X-C motif chemokine ligand 2 | (Zhao et al. 2021) | ||
| Cathepsin H | Promotes neurotoxic polarization, neuroinflammation, and neuronal death | (Fan et al. 2015) | |
| Cathepsin K | Promotes neurotoxic polarization and neuroinflammation | (Wendt et al. 2009) | |
| Cathepsin L | Disrupts microvessel integrity via extracellular matrix degradation | (Gu et al. 2015) | |
| Promotes neurotoxic polarization and neuroinflammation via NF-κB activation | (Xu et al. 2018b; Inoue et al. 2022; Zhang et al. 2025a) | ||
| Activates the NLRP3 inflammasome | (Zhang et al. 2025a) | ||
| Mediates major histocompatibility complex II antigen presentation | (Gresser et al. 2001) | ||
| Cathepsin S | Promotes microglial activation and migration via extracellular matrix degradation | (Hai et al. 2007; Lively and Schlichter 2013; Lowry and Klegeris 2018) | |
| Promotes neurotoxic polarization and neuroinflammation via NF-κB activation | (Wendt et al. 2009; Zhang et al. 2025b) | ||
| Processes the invariant chain to enable major histocompatibility complex II antigen presentation | (Nakagawa et al. 1999; Riese and Chapman 2000; Gresser et al. 2001) | ||
| Cathepsin X | Abolishes γ-enolase neuroprotection against Aβ and lipopolysaccharide via proteolytic cleavage | (Obermajer et al. 2009; Hafner et al. 2013; Pišlar et al. 2017) | |
| Promotes neurotoxic polarization, apoptosis, and neuroinflammation via PI3K/Akt activation | (Wendt et al. 2009; Pišlar et al. 2017, 2020, 2022) | ||
| Astrocytes | Cathepsin B | Degrades Aβ and generates Aβ peptides | (Oberstein et al. 2020) |
| Activates the NLRP3 inflammasome and triggers IL-1β release via caspase-1 | (Qiao et al. 2016) | ||
| Cathepsin C | Enhances neuroinflammation by inducing C-X-C motif chemokine ligand 2 | (Zhao et al. 2021) | |
| Cathepsin K | Alters astrocyte number and phenotype | (Dauth et al. 2011) | |
| Cathepsin L | Mediates major histocompatibility complex II antigen presentation | (Gresser et al. 2001) | |
| Cathepsin S | Contributes to sensory impairment during neuroinflammation in EAE | (Kim et al. 2020) | |
| Oligodendrocytes | Cathepsin X | Impairs oligodendrocyte maturation and differentiation | (Horvat et al. 2025) |
| *Cysteine cathepsins derived from microglia, astrocytes, and neurons affecting oligodendrocyte function. | Cathepsin B* | Impairs remyelination and promotes oligodendrocyte and neuronal damage | (Ma et al. 2007) |
| Cathepsin C* | Enhances demyelination in EAE | (Durose et al. 2019) | |
| Enhances demyelination by inducing C-X-C motif chemokine ligand 2 | (Liang et al. 2016) | ||
|
Produces toxic tumour necrosis factor-α and protective IL-1β and impairs myelin integrity Enhanhes T-cell expansion and tertiary lymphoid structures, resulting in earlier onset and more severe chronic EAE |
(Shimizu et al. 2017) (Liu et al. 2025) |
||
| Cathepsin H* | Contributes to EAE development | (Okada et al. 2018) | |
| Impairs remyelination and promotes oligodendrocyte and neuronal damage | (Ma et al. 2007) | ||
| Cathepsin L* | Contributes to EAE development | (Allan and Yates 2015) | |
| Impairs remyelination and promotes oligodendrocyte and neuronal damage | (Ma et al. 2007) | ||
| Cathepsin X* | Promotes IL-1β and neuroinflammation in EAE | (Allan et al. 2017) | |
| Cathepsin V* | Enhances demyelination | (Shimizu et al. 2017) |
Aβ: amyloid beta, IL: interleukin, EAE: experimental autoimmune encephalomyelitis, NF-κB: nuclear factor kappa-light-chain-enhancer of activated B cells, NLRP3: NOD-leucine rich repeat and pyrin containing protein 3